UB-221
UB-221 is a humanized IgG1 monoclonal antibody inhibitor targeting IgE. UB-221 significantly decreases IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes and inhibits FcԑRI-mediated basophil activation and degranulation. UB-221 reduces IgE level in cynomolgus macaques and human IgE (ε, κ) -transgenic (hIGHE-knockin) mice. UB-221 can be used for asthma and chronic spontaneous urticaria (CSU) research[1].
Product Specifications
CAS Number
[2755114-30-6]
UNSPSC
12352203
Target
Others
Related Pathways
Others
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
References & Citations
[1]Kuo BS, et al. IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms. J Clin Invest. 2022 Aug 1;132 (15) :e157765. |[2]Casale TB. Novel biologics for treatment of chronic spontaneous urticaria. J Allergy Clin Immunol. 2022 Dec;150 (6) :1256-1259.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
138452-APC 100 µL
TOR1B (DQ1, Torsin-1B, Torsin Family 1 Member B, FKSG18, MGC4386) (APC)
Ask
View Details 
GTR15099073 1 Vial
Lentiviral human ZC3H12A shRNA (UAS) - Lentiviral human ZC3H12A shRNA (UAS, RFP) plasmid
Ask
View Details